SA PRO
Free Account
Amicus Therapeutics, Inc.FOLDNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 67% recommend buying.

Consensus Rating
Buy
24 analysts·High coverage
67%
Rating Distribution
Strong Buy
00%
Buy
1667%
Hold
729%
Sell
14%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 22, 2026Jefferies
Jefferies Downgrades Amicus Therapeutics (FOLD) to Hold
Target:$14.50
+1.0%from $14.35
Dec 19, 2025Cantor Fitzgerald
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
Target:$14.50
+1.8%from $14.25
Sep 18, 2025Needham
Needham upgrades Amicus to Buy on reduced regulatory risk
Target:$14.00
+68.5%from $8.31
Oct 17, 2024Bank of America Securities
Amicus Therapeutics (FOLD) PT Raised to $15 at BofA Securities
Target:$15.00
+24.7%from $12.03
May 14, 2024Guggenheim
Amicus upgraded to Buy from Neutral at Guggenheim
Target:$13.00
+43.8%from $9.04
May 9, 2024Morgan Stanley
Amicus Therapeutics (FOLD) PT Lowered to $19 at Morgan Stanley
Target:$19.00
+100.4%from $9.48
Dec 19, 2023Morgan Stanley
Morgan Stanley Upgrades Amicus Therapeutics (FOLD) to Overweight
Target:$20.00
+58.0%from $12.66
May 10, 2021Goldman Sachs
Amicus Therapeutics (FOLD) PT Lowered to $14 at Goldman Sachs
Target:$14.00
+49.1%from $9.39

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance